1-Methyl-5-[[2-[4-(trifluoromethyl)phenyl]benzoyl]amino]indole-2-carboxylic acid | 481659-95-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 1-Methyl-5-[[2-[4-(trifluoromethyl)phenyl]benzoyl]amino]indole-2-carboxylic acid
• CAS: 481659-95-4
• 化学式: C₂₄H₁₇F₃N₂O₃
• 分子量: 438.406
• InChiKey: OEDWWZYYIXCAIW-UHFFFAOYSA-N

物化性质

• 沸点：
  567.2±50.0 °C(Predicted)
• 密度：
  1.34±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  32
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  71.3
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  1-Methyl-5-[[2-[4-(trifluoromethyl)phenyl]benzoyl]amino]indole-2-carboxylic acid 、 (S)-2-amino-N-benzyl-N-methyl-2-phenyl-acetamide 在 N,N-二异丙基乙胺 、 bromo-tris(1-pyrrolidinyl)phosphonium hexafluorophosphate 作用下， 以 二氯甲烷 为溶剂， 以95%的产率得到Dirlotapide
  参考文献：
  名称：

  In vitro and in vivo profile of 5-[(4′-trifluoromethyl-biphenyl-2-carbonyl)-amino]-1H-indole-2-carboxylic acid benzylmethyl carbamoylamide (dirlotapide), a novel potent MTP inhibitor for obesity

  摘要：

  The synthesis of a novel gut selective MTP inhibitor, 5-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-1H-indole-2carboxylic acid benzylmethyl carbamoylamide (dirlotapide), and its in vitro and in vivo profile are described. Dirlotapide (3) demonstrated excellent potency against MTP enzyme in HepG2 cells and canine hepatocytes. This novel MTP inhibitor also showed excellent efficacy when tested in a canine food intake model. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.01.018
• 作为产物：
  描述：

  4-三氟甲基-联苯-2-甲酸 在 lithium hydroxide 、 1-羟基苯并三唑 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 为溶剂， 反应 4.0h， 生成 1-Methyl-5-[[2-[4-(trifluoromethyl)phenyl]benzoyl]amino]indole-2-carboxylic acid
  参考文献：
  名称：

  In vitro and in vivo profile of 5-[(4′-trifluoromethyl-biphenyl-2-carbonyl)-amino]-1H-indole-2-carboxylic acid benzylmethyl carbamoylamide (dirlotapide), a novel potent MTP inhibitor for obesity

  摘要：

  The synthesis of a novel gut selective MTP inhibitor, 5-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-1H-indole-2carboxylic acid benzylmethyl carbamoylamide (dirlotapide), and its in vitro and in vivo profile are described. Dirlotapide (3) demonstrated excellent potency against MTP enzyme in HepG2 cells and canine hepatocytes. This novel MTP inhibitor also showed excellent efficacy when tested in a canine food intake model. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.01.018

文献信息

• [EN] 1,4-DIHYDRONAPHTHYRIDINE DERIVATIVES<br/>[FR] DÉRIVÉS DE 1,4-DIHYDRONAPHTYRIDINE
  申请人：PFIZER PROD INC

  公开号：WO2009056934A1

  公开（公告）日：2009-05-07

  A compound of formulae (I) or a prodrug of the compound or a pharmaceutically acceptable salt thereof of the compound or prodrug, wherein the substituents are as defined in the specification, pharmaceutical compositions containing the compounds useful as calcium channel antagonists, and to methods of treating heart disease and pain.

  一种化合物的公式（I）或该化合物的前药或其药用可接受的盐或前药，其中取代基如规范中所定义，含有该化合物的药用组合物可用作钙通道拮抗剂，并用于治疗心脏病和疼痛的方法。
• Diaryl Ether Derivatives and Uses Thereof
  申请人：Ruggeri B. Roger

  公开号：US20080070887A1

  公开（公告）日：2008-03-20

  Compounds of Formula (I) that act as antagonists at the mu, kappa and/or delta opioid receptors and therefore useful in the treatment of diseases, conditions and/or disorders that benefit from such antagonism in animals are described herein. where R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 are described herein.

  本文描述了具有化学式（I）的化合物，这些化合物在mu、kappa和/或delta阿片受体上起拮抗作用，因此在动物治疗受益于这种拮抗作用的疾病、状况和/或障碍方面具有用处。其中R1、R2、R3、R4、R5和R6如下描述。
• Diaryl, Dipyridinyl and Aryl-Pyridinyl Derivatives and Uses Thereof
  申请人：Ruggeri Roger B.

  公开号：US20080167371A1

  公开（公告）日：2008-07-10

  Compounds of Formula (I) that act as antagonists at the mu, kappa and/or delta opioid receptors and therefore useful in the treatment of diseases, conditions and/or disorders that benefit from such antagonism in animals are described herein. where R, R 1 , R 2a , R 2b , R 3 , R 4 , V, R 6 , R 7 , R 8 , R 9 , W and X are described herein.

  本文描述了化学式（I）的化合物，它们作为mu、kappa和/或delta阿片受体拮抗剂，因此对于需要这种拮抗作用的动物的疾病、状况和/或障碍的治疗是有用的。其中R、R1、R2a、R2b、R3、R4、V、R6、R7、R8、R9、W和X的描述在此处给出。
• Pyrimido [4,5-D] Azepine Derivatives As 5-HT2C Agonists
  申请人：Andrews Mark

  公开号：US20100113422A1

  公开（公告）日：2010-05-06

  The present invention provides a compound of formula (I): or a pharmaceutically acceptable salt thereof wherein the variables R 1 , R 2 , R 3a , R 3b , R 3b , R 3d , and R 100 are as defined herein. The invention is also directed to pharmaceutical compositions comprising the compounds of formula (I) and methods of treating a 5-HT 2c receptor-mediated disorders with a compound of formula (I) or a pharmaceutical composition comprising a compound of formula (I).

  本发明提供了式（I）的化合物：或其药学上可接受的盐，其中变量R1、R2、R3a、R3b、R3b、R3d和R100如本文所定义。本发明还涉及包括式（I）化合物的制药组合物，以及使用式（I）的化合物或包括式（I）的制药组合物治疗5-HT2c受体介导的疾病的方法。
• PPY agonists and uses thereof
  申请人：Pfizer Products Inc.

  公开号：EP2078729A1

  公开（公告）日：2009-07-15

  The invention provides PYY3-36 variants and pegylated derivatives thereof and compositions and methods useful in the treatment of conditions modulated by an NPY Y2 receptor agonist.

  本发明提供了PYY3-36变体及其聚乙二醇化衍生物，以及用于治疗受NPY Y2受体激动剂调节的病症的组合物和方法。